How much help does a vaccine-induced T-cell response need?
Jeffrey S. Weber1 and James J. Mulé2 1Department of Medicine, Keck/University of Southern California School of Medicine and Norris Comprehensive Cancer Center, Los Angeles, California, USA 2University of Michigan Medical Center, Department of Surgery, Ann Arbor, Michigan, USA Address correspondence to: James J. Mulé, University of Michigan Medical Center, Department of Surgery, 1520C MSRBI, Box 0666, Ann Arbor, Michigan 48109-0666, USA. Phone: (734) 647-2779; Fax: (734) 763-4135; E-mail: jimmule@umich.edu. Published March 1, 2001 Currently, much attention is focused on the development of tumor vaccines that incorporate defined tumor-associated antigen (TAA) peptides. Following the first report of the successful molecular cloning of a gene encoding a cytotoxic T lymphocyte-defined (CTL-defined) TAA (1), critical questions have surfaced — not only with respect to the optimal composition of such vaccines (including the choice of TAA, adjuvant, and delivery mode), but also how its effectiv
